NRX Pharmaceuticals, Inc.

Develops novel oral drugs for CNS disorders, targeting suicidal depression and PTSD.

NRXP | US

Overview

Corporate Details

ISIN(s):: US0894821034 (+2 more)
LEI:
Country:: United States of America
Address:: 1201 ORANGE STREET, 19801 WILMINGTON
Website:: https://www.nrxpharma.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for central nervous system (CNS) disorders. The company is focused on addressing the high unmet medical need for treatments for severe bipolar depression and Post-Traumatic Stress Disorder (PTSD), particularly in patients with suicidal ideation. Its lead candidate, NRX-101, is the first investigational oral medication in FDA trials for suicidal bipolar depression and has received Fast Track and Breakthrough Therapy designations. The company's scientific platform is based on targeting the brain's NMDA receptor with a non-hallucinogenic, non-addictive approach. Its pipeline also includes KETAFREE™, a preservative-free ketamine product for suicidal depression.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all NRX Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NRX Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for NRX Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

	Company	Country	Ticker
	LAVA Therapeutics NV Develops bispecific gamma delta T cell engagers for solid and hematologic cancers.	United States of America	LVTX
	Lavipharm S.A. Develops & distributes Rx/OTC medicines, supplements & cosmetics for key therapeutic areas.	Greece	LAVI
	LB PHARMACEUTICALS INC Clinical-stage biopharma developing oral therapies for neuropsychiatric diseases like schizophrenia.	United States of America	LBRX
	Legend Biotech Corp Develops and commercializes CAR-T cell therapies for cancer, including CARVYKTI® for myeloma.	United States of America	LEGN
	LENZ Therapeutics, Inc. Develops a prescription eye drop for presbyopia, the age-related loss of near vision.	United States of America	LENZ
	Lexaria Bioscience Corp. Biotech firm with patented technology improving oral drug delivery and absorption.	United States of America	LEXX
	Lexeo Therapeutics, Inc. Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.	United States of America	LXEO
	LEXICON PHARMACEUTICALS, INC. Develops gene-based drugs for chronic diseases, including treatments for heart failure.	United States of America	LXRX
$LIFECORE BIOMEDICAL, INC. \DE\ Logo$	LIFECORE BIOMEDICAL, INC. \DE\ A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).	United States of America	LFCR
	Liminatus Pharma, Inc. Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.	United States of America	LIMN